Skip to main content

Table 4 Association of tumor ARTN, GFRα1, GFRα3 and SDC3 protein expression with five year relapse-free survival (RFS) and overall survival (OS) in patients with ER-positive/ER-negative or HER2-positive/HER2-negative mammary carcinoma

From: Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, proteins binding ARTEMIN, in mammary carcinoma

  RFS (%) P OS (%) P
ER-positive
ARTN-GFRα1-/ARTN + GFRα1+ 81.0/50.0 0.153 90.5/50.0 0.044
ARTN-GFRα3-/ARTN + GFRα3+ 81.8/50.0 0.199 86.4/50.0 0.138
ARTN- SDC3-/ARTN + SDC3+ 54.2/66.7 0.679 66.7/66.7 0.903
ER-negative
ARTN-GFRα1-/ARTN + GFRα1+ 76.0/16.7 0.002 84.0/16.7 0.001
ARTN-GFRα3-/ARTN + GFRα3+ 75.0/25.0 0.009 81.3/25.0 0.005
ARTN- SDC3-/ARTN + SDC3+ 71.4/50.0 0.532 71.4/50.0 0.532
HER2-positive
ARTN-GFRα1-/ARTN + GFRα1+ 75.0/100.0 0.605 87.5/100.0 0.724
ARTN-GFRα3-/ARTN + GFRα3+ NA   NA  
ARTN- SDC3-/ARTN + SDC3+ NA   NA  
HER2-negative
ARTN-GFRα1-/ARTN + GFRα1+ 78.9/22.2 0.001 86.8/22.2 0.001
ARTN-GFRα3-/ARTN + GFRα3+ 79.1/37.5 0.01 83.7/37.5 0.005
ARTN- SDC3-/ARTN + SDC3+ 64.3/60.0 0.855 71.4/60.0 0.679
  1. Note: NA, not available.
  2. Values in bold are significant (P < 0.05).